pulmonary arterial hypertension

News

MSD eyes March FDA decision on PAH drug sotatercept

MSD has been granted a priority review by the FDA for its pulmonary arterial hypertension (PAH) candidate sotatercept, setting up a decision on the would-be blockbuster by

R&D

JP Morgan 2023 – Lisa Yañez

At JP Morgan Week, pharmaphorum caught up with Lisa Yañez, CEO of Aerami Therapeutics.

Views & Analysis

300 million people worldwide rare disease

Taking the right forecasting approach for rare diseases

There are approximately 7,000 different types of rare disease and researchers estimate that there are more than 300 million people worldwide living with such a condition, according to the N

News

Boost for Merck as Acceleron drug clears key phase 3 hurdle

Merck's $11.5 billion deal to acquire Acceleron last year hinged on the promise of pulmonary arter

News

Merck turns to cardiovascular pipeline for its post-Keytruda...

For some years industry observers have been asking what Merck & Co can do to reduce its reliance on blockbuster cancer immunotherapy Keytruda.

News

Gilead pays $97m to resolve US illegal kickback claims

Gilead has paid $97 million to resolve claims by US authorities that it acted illegally by using a charitable foundation as a conduit to fund co-payments of thousands of Medicare patients t

MSD eyes March FDA decision on PAH drug sotatercept

JP Morgan 2023 – Lisa Yañez

Taking the right forecasting approach for rare diseases

Boost for Merck as Acceleron drug clears key phase 3 hurdle

Merck turns to cardiovascular pipeline for its post-Keytruda...

Gilead pays $97m to resolve US illegal kickback claims

LSX2026: Addressing adult eye cancer, with Roi Raz

Using AI-driven synthetic personas to take your insights fur...

pulmonary arterial hypertension

Editor's Picks